Skip to main content

BeOne Medicines Ltd. (ONC) Stock Forecast

Data as of Aug 3, 2026

Healthcare · Current price $315.00 (-2.09%)

Consensus Target
$399.11
Upside
+26.0%
Analysts
12
Rating
Buy(2.08)

Price Target Range

Low $340.00Consensus $399.11High $436.00
▲ Current $315.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy6
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

ONC vs Sector & Market

MetricONCHealthcare AvgLarge Cap Avg
Analyst Rating2.082.252.42
Analyst Count12819
Target Upside+26.0%+16316.1%+17.1%
P/E Ratio170.442.8543.33

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$1.60B$1.64B$1.66B4
2026-12-31$1.68B$1.72B$1.74B5
2027-03-31$1.56B$1.59B$1.61B3
2027-06-30$1.66B$1.70B$1.72B3
2027-09-30$1.70B$1.73B$1.75B3
2027-12-31$1.86B$1.90B$1.93B3

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$1.66$1.71$1.741
2026-12-31$1.95$2.01$2.041
2027-03-31$1.76$1.81$1.841
2027-06-30$2.15$2.21$2.251
2027-09-30$2.44$2.50$2.551
2027-12-31$4.01$4.12$4.201

Frequently Asked Questions

What is the analyst consensus for ONC?

The consensus among 12 analysts covering BeOne Medicines Ltd. (ONC) is Buy with an average price target of $399.11.

What is the highest price target for ONC?

The highest analyst price target for ONC is $436.00.

What is the lowest price target for ONC?

The lowest analyst price target for ONC is $340.00.

How many analysts cover ONC?

12 analysts have issued ratings for BeOne Medicines Ltd. in the past 12 months.

Is ONC a buy or sell right now?

Based on 12 analyst ratings, ONC has a consensus rating of Buy (2.08/5) with a +26.0% upside to the consensus target of $399.11.

What are the earnings estimates for ONC?

Analysts estimate ONC will report EPS of $1.71 for the period ending 2026-09-30, with revenue estimated at $1.64B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.